Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.



Company Overview and News

15
The Cockroach Bots Roaming Farnborough Air Show - Bloomberg

18h bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
BAESY LMT GEC GE GNE BA BAESF

0
Boeing would be 'thrilled' with role on new UK fighter-defence CEO

2018-07-20 channelnewsasia
Boeing Co , the world's largest planemaker, would be "thrilled" to participate in a new British fighter jet programme, the company's defence chief said, although she said Britain still needed to clarify details about the project.
BAESY DUAVF LMT AM BOE BA BA BAESF

0
Boeing would be 'thrilled' with role on new UK fighter-defence CEO

2018-07-20 reuters
FARNBOROUGH, England (Reuters) - Boeing Co (BA.N), the world’s largest planemaker, would be “thrilled” to participate in a new British fighter jet programme, the company’s defence chief said, although she said Britain still needed to clarify details about the project.
BAESY DUAVF LMT AM BOE BA BA BAESF

15
Cockroach bots roam air show, with a flying taxi on every corner

2018-07-20 thestar
This copy is for your personal non-commercial use only. To order presentation-ready copies of Toronto Star content for distribution to colleagues, clients or customers, or inquire about permissions/licensing, please go to: www.TorontoStarReprints.com
BAESY LMT GEC GE GNE BA BAESF

0
Farnborough 2018: UAE F-16 upgrades announced

2018-07-19 janes
F-16 multirole fighters will receive BAE Systems’ Digital Flight Control Computer, the company announced during the Farnborough International Airshow in the United Kingdom.
BAESY LMT BA BAESF

0
Babcock shares dive on warning over submarine programme slowdown

2018-07-19 telegraph.co.uk
Defence outsourcer Babcock's shares dived after the company warned of a slowdown in spending on the UK’s massive nuclear submarine programme.
BAESY BA BAESF

0
Farnborough 2018: Consultants propose overhaul of Eurofighter consortium

2018-07-19 janes
Management consultants have proposed an overhaul of the Eurofighter industrial and procurement organisations to improve their ability to meet an increasing demand for upgrades and technology insertions from Typhoon operators.
BAESY BA BAESF

0
BAE to Provide Flight Controls for Next-generation F-16s in UAE

2018-07-19 asdnews
Digital Flight Control Computer is the latest high integrity control BAE Systems will provide for F-16 aircraft
BAESY LMT BA BAESF

0
BAE Australia Achieves Peak Production on F-35 Advanced Manufacturing

2018-07-19 asdnews
BAE Systems Australia today welcomed Minister Pyne’s recognition of the completion of the 50th F-35 vertical tail by Marand Precision Engineering and announced that it had achieved peak production rate of machining titanium parts for the program at its Edinburgh Parks facility in South Australia.
BAESY BA BAESF

0
BAE's $1.3 Billion Contract for Howitzer Delayed by U.S. Army - Bloomberg

2018-07-18 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
BAESY BOE BA BA BAESF

0
Terma and BAE sign F-35 Long-Term Price Agreement

2018-07-18 asdnews
Terma and BAE Systems signed a long-term price agreement for the manufacture of composite skins for all three variants of the F-35. The agreement is a continuation of a long-term agreement signed in 2013 covering the manufacture of Large Composite Skins for the Horizontal and Vertical Tail on all variants of the F-35.
BAESY BA BAESF

0
Eurofighter buy would help Belgium secure role in future fighter: BAE

2018-07-17 reuters
FARNBOROUGH, England (Reuters) - Belgium is being offered a possible role in future European combat jet developments if it picks the Eurofighter Typhoon over the U.S.-built F-35, in a fierce contest to rearm the country’s air force, a senior official with Britain’s BAE Systems said.
BAESY LMT DUAVF AM BA BAESF

0
UPDATE 1-Eurofighter buy would help Belgium secure role in future fighter - BAE

2018-07-17 reuters
FARNBOROUGH, England, July 17 (Reuters) - Belgium is being offered a possible role in future European combat jet developments if it picks the Eurofighter Typhoon over the U.S.-built F-35, in a fierce contest to rearm the country’s air force, a senior official with Britain’s BAE Systems said.
BAESY DUAVF AM BA BAESF

0
UPDATE 1-BAE says international partners to join UK fighter project in 2019

2018-07-17 reuters
FARNBOROUGH, England, July 17 (Reuters) - BAE System’s CEO said international partners would be brought in to help to develop Britain’s proposed new fighter jet in 2019, also signalling that teaming up with a rival Franco-German project in future was possible.
BAESY DUAVF AM BA BAESF

0
UTC Aerospace Systems Expanding F-35 MRO Capabilities in the UK

2018-07-17 asdnews
UTC Aerospace Systems, a unit of United Technologies Corp. (NYSE: UTX), announced today that it is expanding its U.K.-based MRO service capabilities to support the F-35 Lightning II. The company is a key supplier to the F-35, providing a range of content including electric and actuation systems, landing gear and air data management sensing technology. The first four of the 138 F-35B’s that the U.K.
BAESY NOC UTX BA BAESF

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

CUSIP: G06940103